SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Relative effectiveness assessments of oncology medicines for pricing and reimbursement decisions in European countries
3 references·2 citing·18 second hop
Relative effectiveness assessments of oncology medicines for pricing and reimbursement decisions in European countries (2016)Relative effectiveness assessments of onc…Actual costs of cancer drugs in 15 European countries (2015)Actual costs of cancer drugs …A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) (2015)A standardised, generic, vali…Relative Effectiveness Assessment of Pharmaceuticals: Similarities and Differences in 29 Jurisdictions (2012)Relative Effectiveness Assess…Validity of Surrogate Endpoints and Their Impact on Coverage Recommendations: A Retrospective Analysis across International Health Technology Assessment Agencies (2021)Validity of Surrogate Endpoin…Weighing of Evidence by Health Technology Assessment Bodies: Retrospective Study of Reimbursement Recommendations for Conditionally Approved Drugs (2018)Weighing of Evidence by Healt…The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials (1997)Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses (2003)Methodological problems in the use of indirect comparisons for evaluating healthcare interventions: survey of published systematic reviews (2009)Health benefit assessment of pharmaceuticals: An international comparison of decisions from Germany, England, Scotland and Australia (2016)Randomized, Controlled Trials, Observational Studies, and the Hierarchy of Research Designs (2000)GRADE guidelines: 3. Rating the quality of evidence (2011)Economic burden of cancer across the European Union: a population-based cost analysis (2013)Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received (2016)The high price of anticancer drugs: origins, implications, barriers, solutions (2017)American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options (2015)Can Price Transparency Contribute to More Affordable Patient Access to Medicines? (2017)Evolution of Average European Medicine Prices: Implications for the Methodology of External Price Referencing (2019)Integrative Review of Managed Entry Agreements: Chances and Limitations (2020)Balancing early market access to new drugs with the need for benefit/risk data: a mounting dilemma (2008)Interrater reliability: the kappa statistic (2012)Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13 (2017)Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement (2013)FDA Approval and Regulation of Pharmaceuticals, 1983-2018 (2020)
this work references cited by second hop

References

  • 2015A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)817 cited
  • 2015Actual costs of cancer drugs in 15 European countries98 cited
  • 2012Relative Effectiveness Assessment of Pharmaceuticals: Similarities and Differences in 29 Jurisdictions64 cited

Cited by

  • 2018Weighing of Evidence by Health Technology Assessment Bodies: Retrospective Study of Reimbursement Recommendations for Conditionally Approved Drugs58 cited
  • 2021Validity of Surrogate Endpoints and Their Impact on Coverage Recommendations: A Retrospective Analysis across International Health Technology Assessment Agencies52 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work